Savara (SVRA) Other Non-Current Assets (2010 - 2026)
Savara (SVRA) reported Other Non-Current Assets of $11.4 million for Q1 2026, up 5.88% year-over-year from $10.7 million in Q1 2025, and down 2.34% quarter-over-quarter from $11.6 million in Q4 2025.
Savara (SVRA) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Other Non-Current Assets data on file, last reported at $11.4 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $11.4 million, up 5.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 million (up 5.88% YoY), and the FY2025 annual result was $11.6 million, up 12.97% from the prior year.
- Other Non-Current Assets fell to $11.4 million in Q1 2026 per SVRA's latest filing, from $11.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $11.6 million in Q4 2025 and troughed at $116000.0 in Q4 2022.
- A 5-year average of $6.7 million and a median of $10.3 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slumped 98.97% in 2022, then jumped 9348.28% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $116000.0 in 2022, then jumped by 9348.28% to $11.0 million in 2023, then retreated by 6.02% to $10.3 million in 2024, then grew by 12.97% to $11.6 million in 2025, then dropped by 2.34% to $11.4 million in 2026.
- Business Quant data shows SVRA's Other Non-Current Assets at $11.4 million in Q1 2026, $11.6 million in Q4 2025, and $990000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 11.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.36 Mn |
| Dec 31, 2025 | 11.64 Mn |
| Sep 30, 2025 | 990,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 10.73 Mn |
| Dec 31, 2024 | 10.30 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 10.63 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Dec 31, 2023 | 10.96 Mn |
| Sep 30, 2023 | 10.50 Mn |
| Jun 30, 2023 | 888,000.00 |
| Mar 31, 2023 | 868,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 9.75 Mn |
| Jun 30, 2022 | 952,000.00 |
| Mar 31, 2022 | 11.06 Mn |
| Dec 31, 2021 | 11.27 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 11.83 Mn |